Payment overview · 2025
General Payments
$130.94
6 reported records · 4 companies
Healthcare provider profile · identity verified
Ma Lwin Lwin Moe, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1487175451
Verified facts
What the public records show
CMS Open Payments records show Ma Lwin Lwin Moe, MD received $130.94 in general payments during 2025 across 6 reported records.
Exact Sciences Corporation accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.54 | 40.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.30 | 35.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.67 | 12.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $15.43 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.94 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.54 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
126 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 949 | 298 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 568 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 168 |
| Losartan Potassium | Losartan Potassium | 503 | 169 |
| Nifedipine Er | Nifedipine | 402 | 127 |
| Metformin Hcl | Metformin Hcl | 372 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 90 |
| Gabapentin | Gabapentin | 245 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 82 |
| Simvastatin | Simvastatin | 217 | 71 |
| Lisinopril | Lisinopril | 196 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 193 | 85 |
| Vascepa | Icosapent Ethyl | 174 | 49 |
| Omeprazole | Omeprazole | 169 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 40 |
| Alendronate Sodium | Alendronate Sodium | 136 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 58 |
| Jardiance | Empagliflozin | 126 | 37 |
| Trulicity | Dulaglutide | 126 | 29 |
| Finasteride | Finasteride | 120 | 43 |
| Famotidine | Famotidine | 118 | 43 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 113 | 46 |
| Incruse Ellipta | Umeclidinium Bromide | 112 | 27 |
| Januvia | Sitagliptin Phosphate | 111 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 28 |
| Montelukast Sodium | Montelukast Sodium | 102 | 35 |
| Eliquis | Apixaban | 97 | 27 |
| Ozempic | Semaglutide | 94 | 20 |
| Ammonium Lactate | Ammonium Lactate | 91 | 34 |
| Alcohol Pads | Alcohol Antiseptic Pads | 81 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 27 |
| Glipizide | Glipizide | 80 | 32 |
| Labetalol Hcl | Labetalol Hcl | 79 | 26 |
| Meclizine Hcl | Meclizine Hcl | 79 | 44 |
| Enalapril Maleate | Enalapril Maleate | 77 | 24 |
| Atenolol | Atenolol | 76 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 21 |
| Single Use Swab | Alcohol Antiseptic Pads | 71 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 23 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 67 | 23 |
| Furosemide | Furosemide | 67 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 26 |
| Donepezil Hcl | Donepezil Hcl | 60 | 18 |
| Farxiga | Dapagliflozin Propanediol | 59 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 25 |
| Diclofenac Epolamine | Diclofenac Epolamine | 53 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 23 |
| Novolog Flexpen | Insulin Aspart | 53 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 26 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 53 | 18 |
| Allopurinol | Allopurinol | 52 | 19 |
| Carvedilol | Carvedilol | 51 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 31 |
| Meloxicam | Meloxicam | 49 | 19 |
| Entresto | Sacubitril/Valsartan | 48 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 17 |
| Levetiracetam | Levetiracetam | 46 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 46 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 40 | 27 |
| Clotrimazole | Clotrimazole | 39 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | 21 |
| Glipizide Er | Glipizide | 36 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 33 |
| Chlorthalidone | Chlorthalidone | 35 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 12 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | 13 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 14 |
| Hydrocortisone | Hydrocortisone | 31 | 12 |
| Ibuprofen | Ibuprofen | 31 | 23 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 11 |
| Folic Acid | Folic Acid | 29 | 12 |
| Rybelsus | Semaglutide | 29 | 11 |
| Azithromycin | Azithromycin | 26 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | 15 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | 15 |
| Metformin Hcl Er | Metformin Hcl | 21 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 12 |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Fluocinonide | Fluocinonide | 18 | 12 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Naproxen | Naproxen | 17 | 16 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 13 |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Ofloxacin | Ofloxacin | 15 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.94 · 6 records | Exact Sciences Corporation | CeQur Simplicity, EVENITY, JARDIANCE, OTEZLA, PROLIA, REPATHA, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error